TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta

Completed

• Conditions: Anemia

• Registration Number: NCT01997892
• Lead Sponsor: Amgen

Brief Summary

To describe the time course of hemoglobin concentration in EU hemodialysis patients switched from methoxy polyethylene glycol-epoetin beta (PEG epoetin beta; Mircera) to darbepoetin alfa (Aranesp).

Detailed Description

This is a multi-centre, observational cohort study of EU hemodialysis patients whose erythropoiesis stimulating agent (ESA) therapy has been switched from PEG epoetin beta to darbepoetin alfa. Data will be collected for the period spanning 14 weeks prior to switch through to 26 weeks post-switch.

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-12-18
• Primary Completion: 2013-06
• Study Completion: 2013-07
• Study First Submitted QC: 2013-11-25
• Study First Posted: 2013-11-28
• Results First Submitted: 2014-04-17
• Results First Submitted QC: 2014-04-17
• Results First Posted: 2014-05-15
• Status Verified: 2014-06
• Last Update Submitted: 2014-06-03
• Last Update Posted: 2014-06-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1027

Inclusion Criteria

• Patients >18 years of age. CKD diagnosis, receiving hemodialysis
• Received PEG epoetin beta for 14weeks prior to switching to darbepoetin alfa and received at least one dose of darbepoetin alfa.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemoglobin Concentration at Monthly Intervals	Month -3, -2, -1 (pre-switch), and Month 1, 2, 3, 4, 5 and 6 (post-switch)	Hemoglobin concentration from 3 months prior to switch to darbepoetin alfa until the end of the observation period.

Secondary Outcome Measures

Name	Time	Method
PEG Epoetin Beta Dose From the Start of the Observation Period Until the Switch	Month -3, Month -2, Month -1	Mean weekly doses were calculated per participant by first calculating a mean daily dose for the interval (by dividing each dose evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose. Weekly doses \>150 μg have been excluded as they were deemed infeasible values derived by the algorithm.
Darbepoetin Alfa Dose From the Switch Date Until the End of the Observation Period	Month 1, 2, 3, 4, 5 and 6	Mean weekly doses were calculated per participant by first calculating a mean daily dose for the interval (by dividing each dose evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose. Weekly doses \>150 μg have been excluded as they were deemed infeasible values derived by the algorithm.
Dose Ratio Measured at the Time of Switch From PEG Epoetin Beta to Darbepoetin Alfa	Week -1 and Week 1	Dose ratio is the average weekly dose of the first darbepoetin alfa dose divided by the average weekly dose of peg-epoetin beta at switch (μg darbepoetin alfa per 1 μg pegylated-epoetin beta).
Hemoglobin Concentration Rate of Change by Period	Thre months prior to switch and 6 months after the switch	The hemoglobin rate of change is the maximum monthly increase and maximum monthly decrease for the pre- and post-switch periods. Within each period, the difference was calculated between each hemoglobin value and the most recent hemoglobin value taken at least 28 days previously. The rate of change was calculated by dividing this difference by the number of days in the interval and multiplying by 28. The maximum and minimum rate of change was then determined per participant.
Percentage of Participants With Hemoglobin Excursions	Month -3, -2, -1, 1, 2, 3, 4, 5 and 6	The percentage of participants with at least one hemoglobin excursion, defined as hemoglobin concentrations below 10.0 g/dL and above 12.0 g/dL during the pre- and post-switch periods.

Trial Locations

Locations (1)

Research Site; 🇨🇭 Sion, Switzerland